Starting Wegovy as a new customer: what you're deciding and what actually happens

Is Wegovy actually the right fit for where you're starting?

The first decision isn't which dose to begin on, it's whether Wegovy suits your situation at all. Wegovy (semaglutide) is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't determine suitability: a prescriber considers your full medical picture, including any medicines you take, your history with conditions like pancreatitis, and whether you're pregnant, trying to conceive, or breastfeeding, in those circumstances Wegovy is not recommended.

It's also worth being clear about what Wegovy is not. Ozempic is semaglutide too, but it carries a licence for type 2 diabetes rather than weight management, and it isn't the right route for people seeking weight-loss treatment. Wegovy is the specific formulation and brand licensed for that purpose in the UK, as confirmed by the NHS medicines information for semaglutide. New patients sometimes arrive having heard about semaglutide in general, our overview of semaglutide for weight management unpacks the distinction clearly if you'd like more background before your consultation.

If you have any doubt about fit, the right place to resolve it is a conversation with a prescriber, not a forum.

What starting Wegovy actually involves, the titration path and what to expect

As a new Wegovy patient, treatment opens at 0.25mg once weekly. That low starting dose exists for a practical reason: the GI side effects that some people experience (nausea, loose stools, indigestion, fatigue) are almost always most pronounced early on and are significantly reduced when the dose climbs slowly. The titration pathway moves upward roughly every four weeks, through 0.5mg, 1.0mg and 1.7mg, toward the standard 2.4mg maintenance dose. If you're considering starting for the first time, our guide for new Wegovy patients walks through what to expect at each stage of that journey. In January 2026 the MHRA also approved a higher 7.2mg dose for people with a BMI of 30 or above, and a dedicated single-dose 7.2mg pen followed in April 2026, meaning the ceiling for new patients entering treatment now is meaningfully higher than it was a year ago.

The titration pace is set by your prescriber, not by a countdown timer. If a particular dose step causes persistent side effects, slowing the increase is a clinical option, something to raise with your prescriber rather than manage alone. At any dose step, missing a dose, the storage requirements and what to do if you're unwell are all covered in the Patient Information Leaflet that comes with your treatment; the Wegovy SmPC on the electronic Medicines Compendium holds the complete clinical detail.

Most new patients want to know what the pen itself looks like when it arrives. It comes in a plain, unbranded box via DPD with tracked delivery (there's nothing on the outside to identify the contents) and needs to go straight into the fridge on arrival.

Understanding the results evidence, and where realistic expectations sit

The trial evidence for Wegovy is substantial. In the STEP 1 study (68 weeks, semaglutide 2.4mg versus placebo) participants lost an average of around 15% of their body weight alongside lifestyle changes. That figure is meaningful, but it's an average across thousands of participants: individual outcomes vary, and results depend on sustained adherence, dietary effort and physical activity alongside the medicine. No legitimate service should promise you a specific number.

For context on how Wegovy compares with tirzepatide (Mounjaro), the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025 found greater average weight loss with tirzepatide, though the newer Wegovy 7.2mg dose narrows that gap considerably. Which medicine is the better clinical choice for you is a question your prescriber is best placed to answer once they know your full picture. Our Wegovy treatment page has more on how the evidence shapes the clinical decision, and if you're curious about what people who've already been through the process say, you can read patient perspectives on Wegovy.

Worth noting: if you've reached six months at the highest dose you can tolerate and lost less than 5% of your starting weight, NICE guidance suggests reviewing whether continuing makes sense. Your prescriber would discuss this with you directly.

Choosing a legitimate route, and why the regulatory layer matters for new patients

Starting Wegovy for the first time means making a choice about where to get it. On the NHS, Wegovy is available through specialist weight management services under NICE's recommendations, but waiting lists are long and the eligibility criteria are specific. The private route (through a regulated online pharmacy) is a genuine and legal alternative for people who don't meet the current NHS thresholds or prefer not to wait. The single requirement is that it must involve a real prescription from a registered prescriber after a proper clinical review. If you're also weighing up the broader treatment landscape, our guide to starting semaglutide for the first time covers what the process looks like across different formulations and how to approach that initial clinical conversation.

When you start with nume, your consultation goes to a GPhC-registered Independent Prescriber the same day, a clinician reads your answers, not software. Identity and weight are verified, and if treatment is clinically appropriate, it's dispatched the same day for free next-working-day delivery. You can read more about who we are and how our pharmacy operates, and our clinical team's approach is outlined on our prescriber profile page.

One practical thing to check before starting anywhere: every legitimate online pharmacy in the UK is required to be registered with the General Pharmaceutical Council. You can verify any pharmacy at the GPhC register, nume's registration number is 9012878. Sellers offering Wegovy without a prescription are operating illegally, and the MHRA has flagged counterfeit weight-loss pens as a genuine patient-safety risk. If you're comparing options, our cost context page explains what legitimate pricing includes and what to watch for.

If you're ready to find out whether Wegovy is right for you, start your free consultation, there's no obligation, and the assessment is thorough.